# Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs

> **NCT03981211** · NA · UNKNOWN · sponsor: **Kirby Institute** · enrollment: 60 (estimated)

## Conditions studied

- Hepatitis C
- Liver Inflammation
- Liver Cirrhoses

## Interventions

- **DRUG:** Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet
- **DRUG:** Sofosbuvir 400 MG + Glecaprevir/Pibrentasvir 100 MG-40 MG Oral Tablet

## Key facts

- **NCT ID:** NCT03981211
- **Lead sponsor:** Kirby Institute
- **Sponsor class:** OTHER_GOV
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-02-12
- **Primary completion:** 2025-02-12
- **Final completion:** 2025-02-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2024-03-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03981211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03981211, "Treatment of HOsPitalised Inpatients for Hepatitis C (TOPIC): Therapeutic Intervention Enhancing Care Linkage in People Who Inject Drugs". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03981211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*